Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions prominently center around the methodologies of PCI versus CABG and the appropriate endpoints for myocardial revascularization trials. For instance, various comments question the use of all-cause mortality as a primary endpoint, highlighting a tone of critical analysis. Phrases like 'obligada lectura' and 'must read' suggest that participants find the publication crucial for professionals treating ischemic heart disease, reflecting both urgency and seriousness in addressing the trial comparisons. The tone across the discussions is scholarly yet engaged, as participants refer to specific studies and express curiosity about the implications of the findings.
Most discussions show a general consensus on the importance of the findings discussed in the publication.
Posts display a high level of curiosity, with many members actively seeking clarification or additional viewpoints.
Many participants delve deeply into the study's methodology and implications, showcasing thoughtful analysis.
There is a strong belief that the publication could influence future clinical practices regarding cardiac revascularization.
#EXCEL An interesting opinion published in 12.2018 (last year!), suggesting how PCI vs. CABG trials may be gamed against CABG The list of authors is an impressive and international group of expert surgeons Main points in thread (1/9) https://t.co/p6nxZ3gRZC https://t.co/dXoQgEkjfs
More good reading on understanding EXCEL and other revascularization trials here> In @CircAHA https://t.co/UkmHUL2W8n I love the subtitle. Perhaps #BeyondThePrintedWord would be a good hashtag. https://t.co/DFDrWFU5CF
このSCAIのAMI基準というのはUDに比べてCABGで10倍、PCIで1.8倍ほどAMIの診断を増やすということで、PCIに有利となる基準であることが報告されています。 続 https://t.co/WYfDHO622O https://t.co/xh83My9gRn
Obligada lectura para todos profesionales implicados en el tratamiento de pacientes con cardiopatía isquemica. Myocardial Revascularization Trials | Circulation https://t.co/3iH3EJcvJB
Beautiful summary written by most serious investigator in coronary artery revascularization. https://t.co/j6sOVOMUw8
@kaulcsmc @pomyers @irbaz_hameed @drmikefarkouh 1/2- The underlying principle is the same. Without any explicit calculations, I think that myocardial revascularization trials of PCI vs. CABG tend to be carried out in populations with a high enough attributable risk to be reasonable for all-cause mortality endpoints.
A critical analysis of the EXCEL study reveals significant issues in medical research design. This video discusses five-year outcomes for patients with left main coronary artery disease, comparing PCI and CABG…
RT @djc795: @kaulcsmc @pomyers @irbaz_hameed @drmikefarkouh 1/2- The underlying principle is the same. Without any explicit calculations,…
RT @kaulcsmc: @djc795 @pomyers @irbaz_hameed @drmikefarkouh OK David, you have a point with screening trials. But what about my original qu…
@kaulcsmc @pomyers @irbaz_hameed @drmikefarkouh 1/2- The underlying principle is the same. Without any explicit calculations, I think that myocardial revascularization trials of PCI vs. CABG tend to be carried out in populations with a high enough attributable risk to be reasonable for all-cause mortality endpoints.
@djc795 @pomyers @irbaz_hameed @drmikefarkouh OK David, you have a point with screening trials. But what about my original question regarding myocardial revascularization trials? Care to share you viewpoint?
Should cause specific or overall mortality be used as the end point in myocardial revascularization trials? @BryceRobinsonMD and others answer this question in the most recent issue of @JAMAInternalMed https://t.co/MbuHkQFLjj 3/4
RT @BryceRobinsonMD: Our analysis on mortality in RCTs comparing CABG and PCI out now on @JAMAInternalMed. All cause mortality should be us…
Our analysis on mortality in RCTs comparing CABG and PCI out now on @JAMAInternalMed. All cause mortality should be used as primary end point for myocardial revascularization trials #cabg #pci @WCM_CTSurgery https://t.co/Xx0jVQJ04p
RT @KagiyamaNobu: このSCAIのAMI基準というのはUDに比べてCABGで10倍、PCIで1.8倍ほどAMIの診断を増やすということで、PCIに有利となる基準であることが報告されています。 続 https://t.co/WYfDHO622O https:/…
RT @KagiyamaNobu: このSCAIのAMI基準というのはUDに比べてCABGで10倍、PCIで1.8倍ほどAMIの診断を増やすということで、PCIに有利となる基準であることが報告されています。 続 https://t.co/WYfDHO622O https:/…
RT @KagiyamaNobu: このSCAIのAMI基準というのはUDに比べてCABGで10倍、PCIで1.8倍ほどAMIの診断を増やすということで、PCIに有利となる基準であることが報告されています。 続 https://t.co/WYfDHO622O https:/…
このSCAIのAMI基準というのはUDに比べてCABGで10倍、PCIで1.8倍ほどAMIの診断を増やすということで、PCIに有利となる基準であることが報告されています。 続 https://t.co/WYfDHO622O https://t.co/xh83My9gRn
RT @sajannarayanan: @GreggWStone https://t.co/o0xAN3mrmG... SCAI definition does identify more ‘MI’ in CABG v PCI as compared to UDMI.. agr…
@HighSTEACS Heraklit Panta Rhei : Myocardial Revascularization Trials | Circulation https://t.co/DGgcUCeVHz https://t.co/D3ScBZPpyC
RT @HighSTEACS: @chapdoc1 Data from #EXCEL on use of #UDMI criteria for peri procedural MI have not been publicly disclosed but this excell…
@chapdoc1 Data from #EXCEL on use of #UDMI criteria for peri procedural MI have not been publicly disclosed but this excellent #WhitePaper from @CircAHA explains likely impact https://t.co/ZBZPPmxOZw https://t.co/p5fOHjuURq
RT @Ekonsalud: Revisión de resultados en tratamiento de isquemia miocardica y el rol de la cirugía de revascularizacion Myocardial Revascul…
RT @galdamiz65: Obligada lectura para todos profesionales implicados en el tratamiento de pacientes con cardiopatía isquemica. Myocardial…
RT @Ekonsalud: Revisión de resultados en tratamiento de isquemia miocardica y el rol de la cirugía de revascularizacion Myocardial Revascul…
RT @galdamiz65: Obligada lectura para todos profesionales implicados en el tratamiento de pacientes con cardiopatía isquemica. Myocardial…
Revisión de resultados en tratamiento de isquemia miocardica y el rol de la cirugía de revascularizacion Myocardial Revascularization Trials | Circulation https://t.co/bYXRHH8y3X
RT @galdamiz65: Obligada lectura para todos profesionales implicados en el tratamiento de pacientes con cardiopatía isquemica. Myocardial…
RT @VictorDayan1: Beautiful summary written by most serious investigator in coronary artery revascularization. https://t.co/j6sOVOMUw8
RT @galdamiz65: Obligada lectura para todos profesionales implicados en el tratamiento de pacientes con cardiopatía isquemica. Myocardial…
RT @galdamiz65: Obligada lectura para todos profesionales implicados en el tratamiento de pacientes con cardiopatía isquemica. Myocardial…
RT @galdamiz65: Obligada lectura para todos profesionales implicados en el tratamiento de pacientes con cardiopatía isquemica. Myocardial…
Obligada lectura para todos profesionales implicados en el tratamiento de pacientes con cardiopatía isquemica. Myocardial Revascularization Trials | Circulation https://t.co/3iH3EJcvJB
RT @VictorDayan1: Beautiful summary written by most serious investigator in coronary artery revascularization. https://t.co/j6sOVOMUw8
RT @VictorDayan1: Beautiful summary written by most serious investigator in coronary artery revascularization. https://t.co/j6sOVOMUw8
RT @VictorDayan1: Beautiful summary written by most serious investigator in coronary artery revascularization. https://t.co/j6sOVOMUw8
RT @VictorDayan1: Beautiful summary written by most serious investigator in coronary artery revascularization. https://t.co/j6sOVOMUw8
RT @VictorDayan1: Beautiful summary written by most serious investigator in coronary artery revascularization. https://t.co/j6sOVOMUw8
Worth reading and a sensible analysis of revasc trials up to now. https://t.co/4lsDN3e6EP
RT @pomyers: #EXCEL An interesting opinion published in 12.2018 (last year!), suggesting how PCI vs. CABG trials may be gamed against CABG…
RT @drjohnm: More good reading on understanding EXCEL and other revascularization trials here> In @CircAHA https://t.co/UkmHUL2W8n I love…
RT @drjohnm: More good reading on understanding EXCEL and other revascularization trials here> In @CircAHA https://t.co/UkmHUL2W8n I love…
RT @VictorDayan1: Beautiful summary written by most serious investigator in coronary artery revascularization. https://t.co/j6sOVOMUw8
RT @pomyers: #EXCEL An interesting opinion published in 12.2018 (last year!), suggesting how PCI vs. CABG trials may be gamed against CABG…
Beautiful summary written by most serious investigator in coronary artery revascularization. https://t.co/j6sOVOMUw8
Myocardial Revascularization in: #EXCELTrial conflict times #CABG @tomcnguyen @ArieBlitzMD @DRASCIOGLU @OuzounianMD @TsuyoshiKaneko1 @jenn_cy_chung @FernandoBiguria @GBisleri @dompagano @HirooTakayamaMD @miguelpinon_73 @FaisalBakaeen @LorraineC_MD https://t.co/yc8U6WfnMX
RT @drjohnm: More good reading on understanding EXCEL and other revascularization trials here> In @CircAHA https://t.co/UkmHUL2W8n I love…
RT @drjohnm: More good reading on understanding EXCEL and other revascularization trials here> In @CircAHA https://t.co/UkmHUL2W8n I love…
RT @pomyers: #EXCEL An interesting opinion published in 12.2018 (last year!), suggesting how PCI vs. CABG trials may be gamed against CABG…
RT @pomyers: #EXCEL An interesting opinion published in 12.2018 (last year!), suggesting how PCI vs. CABG trials may be gamed against CABG…
RT @pomyers: #EXCEL An interesting opinion published in 12.2018 (last year!), suggesting how PCI vs. CABG trials may be gamed against CABG…
RT @pomyers: #EXCEL An interesting opinion published in 12.2018 (last year!), suggesting how PCI vs. CABG trials may be gamed against CABG…
RT @drjohnm: More good reading on understanding EXCEL and other revascularization trials here> In @CircAHA https://t.co/UkmHUL2W8n I love…
RT @pomyers: #EXCEL An interesting opinion published in 12.2018 (last year!), suggesting how PCI vs. CABG trials may be gamed against CABG…
RT @drjohnm: More good reading on understanding EXCEL and other revascularization trials here> In @CircAHA https://t.co/UkmHUL2W8n I love…
More good reading on understanding EXCEL and other revascularization trials here> In @CircAHA https://t.co/UkmHUL2W8n I love the subtitle. Perhaps #BeyondThePrintedWord would be a good hashtag. https://t.co/DFDrWFU5CF
RT @pomyers: #EXCEL An interesting opinion published in 12.2018 (last year!), suggesting how PCI vs. CABG trials may be gamed against CABG…
RT @pomyers: #EXCEL An interesting opinion published in 12.2018 (last year!), suggesting how PCI vs. CABG trials may be gamed against CABG…
RT @pomyers: #EXCEL An interesting opinion published in 12.2018 (last year!), suggesting how PCI vs. CABG trials may be gamed against CABG…
RT @pomyers: #EXCEL An interesting opinion published in 12.2018 (last year!), suggesting how PCI vs. CABG trials may be gamed against CABG…
RT @pomyers: #EXCEL An interesting opinion published in 12.2018 (last year!), suggesting how PCI vs. CABG trials may be gamed against CABG…
RT @pomyers: #EXCEL An interesting opinion published in 12.2018 (last year!), suggesting how PCI vs. CABG trials may be gamed against CABG…
RT @pomyers: #EXCEL An interesting opinion published in 12.2018 (last year!), suggesting how PCI vs. CABG trials may be gamed against CABG…
RT @pomyers: #EXCEL An interesting opinion published in 12.2018 (last year!), suggesting how PCI vs. CABG trials may be gamed against CABG…
RT @pomyers: #EXCEL An interesting opinion published in 12.2018 (last year!), suggesting how PCI vs. CABG trials may be gamed against CABG…
RT @pomyers: #EXCEL An interesting opinion published in 12.2018 (last year!), suggesting how PCI vs. CABG trials may be gamed against CABG…
RT @pomyers: #EXCEL An interesting opinion published in 12.2018 (last year!), suggesting how PCI vs. CABG trials may be gamed against CABG…
RT @pomyers: #EXCEL An interesting opinion published in 12.2018 (last year!), suggesting how PCI vs. CABG trials may be gamed against CABG…
#EXCEL An interesting opinion published in 12.2018 (last year!), suggesting how PCI vs. CABG trials may be gamed against CABG The list of authors is an impressive and international group of expert surgeons Main points in thread (1/9) https://t.co/p6nxZ3gRZC https://t.co/dXoQgEkjfs
RT @CircIntv: Myocardial Revascularization Trials. Working collaboratively to define the best treatment strategy for CAD patients https://t…
RT @CircAHA: #WhitePaper: Myocardial Revascularization trials: Beyond the printed word https://t.co/56nlajrQlI https://t.co/VoyOWu40i2
RT @CircAHA: #WhitePaper: Myocardial Revascularization trials: Beyond the printed word https://t.co/56nlajrQlI https://t.co/VoyOWu40i2
RT @CircAHA: #WhitePaper: Myocardial Revascularization trials: Beyond the printed word https://t.co/56nlajrQlI https://t.co/VoyOWu40i2